Department for Medicine (Gastroenterology, Infectious diseases, Rheumatology), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Campus Benjamin Franklin, Berlin, Germany.
Clinician Scientist Program, Berlin Institute of Health, Berlin, Germany.
Mucosal Immunol. 2021 May;14(3):566-573. doi: 10.1038/s41385-021-00384-9. Epub 2021 Feb 19.
Viral infections with SARS-CoV-2 can cause a multi-facetted disease, which is not only characterized by pneumonia and overwhelming systemic inflammatory immune responses, but which can also directly affect the digestive system and infect intestinal epithelial cells. Here, we review the current understanding of intestinal tropism of SARS-CoV-2 infection, its impact on mucosal function and immunology and summarize the effect of immune-suppression in patients with inflammatory bowel disease (IBD) on disease outcome of COVID-19 and discuss IBD-relevant implications for the clinical management of SARS-CoV-2 infected individuals.
SARS-CoV-2 病毒感染可引起多方面的疾病,不仅表现为肺炎和全身性炎症免疫反应过度,还可直接影响消化系统并感染肠道上皮细胞。在此,我们综述了目前对 SARS-CoV-2 感染肠道趋向性的认识,及其对黏膜功能和免疫的影响,并总结了炎症性肠病 (IBD) 患者免疫抑制对 COVID-19 疾病结局的影响,同时讨论了 SARS-CoV-2 感染个体临床管理中与 IBD 相关的影响。